Cytokinetics, Inc.
Cytokinetics Board Director Resignation and Shareholder Approvals at 2024 Annual Meeting
Summary
On May 15, 2024, Cytokinetics, Incorporated announced that Sandford D. Smith resigned from the Board of Directors immediately before the company's 2024 annual meeting of stockholders. The meeting also saw the approval of several proposals, including the amendment of the Employee Stock Purchase Plan to authorize an additional 300,000 shares of common stock, the election of two new Class II Directors, the ratification of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024, and an advisory vote approving the compensation of the named executive officers.
Profitelligence Alerts
Get alerts for CYTK
Be first to know when Cytokinetics, Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Cytokinetics, Inc.
Cytokinetics, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel muscle activators as potential treatments for debilitating diseases. Primarily, the company's work aims to address unmet medical needs in the fields of neurology and cardiology, offering therapeutic solutions that target muscle function. Cytokinetics' research centers on small molecule drugs that modulate muscle performance, which could significantly aid patients suffering from heart failure, amyotrophic lateral sclerosis (ALS), and other muscle-related conditions. The company is actively involved in clinical trials and collaborates with other notable entities in its quest for innovative medical advancements. Its contributions to the healthcare sector exemplify the growing role of targeted therapy in improving patient outcomes. Headquartered in South San Francisco, California, Cytokinetics operates as a key player in the biotechnology landscape, with a commitment to pioneering treatments that leverage the complex mechanisms of muscle biology.
Official SEC Documents
Advertisement